MELINTA THERAPEUTICS INC (MLNT) Stock Price, Quote, News and Overview
NASDAQ:MLNT - Nasdaq -
MLNT Quote, Performance and Key Statistics
0.5
-0.03 (-5.7%)
The current stock price of MLNT is 0.5 null. In the past month the price decreased by -68.15%. In the past year, price decreased by -90.57%.
About MLNT
Company Profile
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.
Company Info
MELINTA THERAPEUTICS INC
44 WHIPPANY ROAD
MORRISTOWN NJ 07960
CEO: John H. Johnson
Phone: 908-617-1309
MELINTA THERAPEUTICS INC / MLNT FAQ
What is the stock price of MELINTA THERAPEUTICS INC today?
The current stock price of MLNT is 0.5 null. The price decreased by -5.7% in the last trading session.
What is the ticker symbol for MELINTA THERAPEUTICS INC stock?
The exchange symbol of MELINTA THERAPEUTICS INC is MLNT and it is listed on the Nasdaq exchange.
On which exchange is MLNT stock listed?
MLNT stock is listed on the Nasdaq exchange.
What is MELINTA THERAPEUTICS INC worth?
MELINTA THERAPEUTICS INC (MLNT) has a market capitalization of 6.88M null. This makes MLNT a Nano Cap stock.
Should I buy MELINTA THERAPEUTICS INC (MLNT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MLNT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MLNT, evaluating the profitability, health, valuation and growth aspects
- MELINTA THERAPEUTICS INC (MLNT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MELINTA THERAPEUTICS INC (MLNT) Sales and EPS estimates to see what analysts future expectations are.
- MELINTA THERAPEUTICS INC (MLNT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MELINTA THERAPEUTICS INC (MLNT) Insider and Institutional Ownership to learn about the owners and their transactions.
- MELINTA THERAPEUTICS INC (MLNT) Stock Chart to make your own analysis
- MELINTA THERAPEUTICS INC (MLNT) Latest news and press-releases to stay up to date.
Does MELINTA THERAPEUTICS INC (MLNT) stock pay dividends?
MLNT does not pay a dividend.
What is the Price/Earnings (PE) ratio of MELINTA THERAPEUTICS INC (MLNT)?
MELINTA THERAPEUTICS INC (MLNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.47).
MLNT Technical Analysis
MLNT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLNT. Both the profitability and financial health of MLNT have multiple concerns.
MLNT Financial Highlights
Over the last trailing twelve months MLNT reported a non-GAAP Earnings per Share(EPS) of -9.469999999999999. The EPS increased by 19.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -393.39% | ||
| ROA | -140.14% | ||
| ROE | N/A | ||
| Debt/Equity | -1.47 |
MLNT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to MLNT. The Buy consensus is the average rating of analysts ratings from 3 analysts.